Compare PLSM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSM | FEMY |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 11.5M |
| IPO Year | 2025 | 2021 |
| Metric | PLSM | FEMY |
|---|---|---|
| Price | $1.40 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 12.6K | ★ 104.8K |
| Earning Date | 08-31-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $294.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $1.27 | $0.29 |
| 52 Week High | $12.97 | $6.29 |
| Indicator | PLSM | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 28.23 | 36.99 |
| Support Level | N/A | $0.33 |
| Resistance Level | $2.64 | $1.55 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 4.65 | 36.46 |
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.